Allosteric modulation of the Cannabinoid CB1 receptor

Molecular Pharmacology

Volumn 68, Issue 5, 2005, Pages 1484-1495

  Price, Martin R ^a   Baillie, Gemma L ^a   Thomas, Adéle ^a   Stevenson, Lesley A ^a   Easson, Morag ^b   Goodwin, Richard ^b   McLean, Adéle ^b   McIntosh, Lorraine ^b   Goodwin, Gillian ^b   Walker, Glenn ^b   Westwood, Paul ^b   Marrs, Julia ^b   Thomson, Fiona ^b   Cowley, Phillip ^b   Christopoulos, Arthur ^c   Pertwee, Roger G ^a   Ross, Ruth A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 ETHYL 5 FLUORO 1H INDOLE 2 CARBOXYLIC ACID(2 (4 DIMETHYLAMINOPHENYL) ETHYL]AMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 CHLORO 3 ETHYL 1H INDOLE 2 CARBOXYLIC ACID(1 BENZYLPYRROLIDIN 3 YL)AMIDE; 5 CHLORO 3 ETHYL 1H INDOLE 2 CARBOXYLIC ACID[2 (4 PIPERIDIN 1 YLPHENYL)ETHYL]AMIDE; AMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); ORG 27569 0; ORG 27759 0; ORG 29647 1; RADIOLIGAND; RIMONABANT; SULFUR 35; TRITIUM; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CONFORMATION; CONTROLLED STUDY; DATA ANALYSIS; DISSOCIATION; DRUG EFFECT; DRUG RECEPTOR BINDING; KINETICS; MALE; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; VAS DEFERENS;

ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; CYCLOHEXANOLS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MALE; MICE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; VAS DEFERENS;

EID: 24044539957     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.016162     Document Type: Article

References (35)

1. Bifulco M and Di Marzo V (2002) Targeting the endocannabinoid system in cancer therapy: a call for further research Nat Med 8:547-550.
2. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
3. Christopoulos A (1998) Assessing the distribution of parameters in models of ligandreceptor interaction: to log or not to log. Trends Pharmacol Sci 19:351-357.
4. Christopoulos A (2000) Quantification of allosteric interactions at G protein-coupled Receptors using radioligand binding assays, in Current Protocols in Pharmacology (Enna SJ ed) pp 1.22.1-1.22.40. John Wiley & Sons, New York.
5. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
6. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
7. Cravatt BF and Lichtman AH (2004) The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61:149-160.
8. Devlin MG and Christopoulos A (2002) Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J Neurochem 80:1095-1102.
9. Di Marzo V, Bifulco M, and De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784.
10. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
11. Ehlert FJ and Rathbun BE (1990) Signaling through the muscarinic receptor-adenylate cyclase system of the heart is buffered against GTP over a range of concentrations. Mol Pharmacol 38:148-158.
12. Furchgott RF (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res 3:21-55.
13. Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58:1412-1423.
14. Horvath TL (2003) Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Investig 112:323-326.
15. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
16. Idris AI, van't Hof RJ, Greig IR, Ridge SA, Ross RA, and Ralston SH (2005) Regulation of bone mass, bone loss and osteoclast activity. Nat Med 11:774-779.
17. Iversen L and Chapman V (2002) Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2:50-55.
18. Kenakin T and Beek D (1982) In vitro studies on the cardiac activity of prenalterol with reference to use in congestive heart failure. J Pharmacol Exp Ther 220:77-85.
19. Kostenis E and Mohr K (1996) Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci 17:280-283.
20. Lazareno S and Birdsall NJM (1995) Detection, quantitation and verification of allosteric interactions of agents with labeled and unlabeled ligands at G proteincoupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
21. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prezeau L, Pin JP, Thomsen C, and Kuhn R (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55:453-461.
22. May LT and Christopoulos A (2003) Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol 3:551-556.
23. Neubig RR, Spedding M, Kenakin T, and Christopoulos A (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55:597-606.
24. Parmentier ML, Prezeau L, Bockaert J, and Pin JP (2002) A model for the functioning of family 3 GPCRs. Trends Pharmacol Sci 23:268-274.
25. Pedder EK, Eveleigh P, Poyner D, Hulme EC, and Birdsall NJM (1991) Modulation of the structure-binding relationships of antagonists for muscarinic acetylcholine receptor subtypes. Br J Pharmacol 103:1561-1567.
26. 2 receptors. Pharmacol Ther 74:129-180.
27. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611.
28. Pertwee RG (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95:165-174.
29. 1 receptors. Life Sci 76:1307-1324.
30. Pertwee RG and Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66:101-121.
31. Randall MD, Harris D, Kendall DA, and Ralevic V (2002) Cardiovascular effects of cannabinoids. Pharmacol Ther 95:191-202.
32. Rice ASC, Farquhar-Smith WP, and Nagy I (2002) Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66:243-256.
33. Ross RA (2003) Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140:790-801.
34. Watson C, Jenkinson S, Kazmierski W, and Kenakin T (2005) The CCR5 receptorbased mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67:1268-1282.
35. Zahn K, Eckstein N, Trankle C, Sadee W, and Mohr K (2002) Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J Pharmacol Exp Ther 301:720-728.